A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.

R. N. Weinreb, D. R. Caldwell, S. M. Goode, B. L. Horwitz, R. Laibovitz, C. E. Shrader, R. H. Stewart, A. T. Williams

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

In 352 patients with primary open-angle glaucoma or ocular hypertension, a multicenter double-masked, parallel-group clinical study compared the effects on intraocular pressure and ocular comfort of 0.5% betaxolol ophthalmic solution, a cardioselective beta-adrenergic blocking agent, with 0.25% betaxolol suspension. With twice-daily dosages, baseline intraocular pressure was significantly reduced (P = .0005), with no significant difference between the two groups, at Week 2 and at Months 1, 2, and 3. Further, the prevalence of ocular discomfort upon topical instillation was significantly lower for 0.25% betaxolol suspension than for 0.5% betaxolol solution (P = .0005).

Original languageEnglish (US)
Pages (from-to)189-192
Number of pages4
JournalAmerican journal of ophthalmology
Volume110
Issue number2
DOIs
StatePublished - Aug 15 1990
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.'. Together they form a unique fingerprint.

Cite this